Compare VRT & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VRT | GILD |
|---|---|---|
| Founded | N/A | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 142.1B | 155.3B |
| IPO Year | 2018 | 2003 |
| Metric | VRT | GILD |
|---|---|---|
| Price | $305.23 | $125.58 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 20 | 18 |
| Target Price | ★ $269.44 | $148.39 |
| AVG Volume (30 Days) | 5.6M | ★ 7.8M |
| Earning Date | 04-22-2026 | 05-07-2026 |
| Dividend Yield | 0.08% | ★ 2.55% |
| EPS Growth | 166.41 | ★ 1684.21 |
| EPS | 0.99 | ★ 1.61 |
| Revenue | N/A | ★ $24,689,000,000.00 |
| Revenue This Year | $34.04 | $4.68 |
| Revenue Next Year | $23.82 | $6.04 |
| P/E Ratio | $328.48 | ★ $76.82 |
| Revenue Growth | N/A | ★ 9.98 |
| 52 Week Low | $110.06 | $107.75 |
| 52 Week High | $379.94 | $157.29 |
| Indicator | VRT | GILD |
|---|---|---|
| Relative Strength Index (RSI) | 46.09 | 44.56 |
| Support Level | $284.53 | $116.55 |
| Resistance Level | $345.18 | $126.81 |
| Average True Range (ATR) | 17.29 | 3.53 |
| MACD | 0.78 | 0.17 |
| Stochastic Oscillator | 35.58 | 45.06 |
Vertiv has roots tracing back to 1946 when its founder, Ralph Liebert, developed an air-cooling system for mainframe data rooms. As computers started making their way into commercial applications in 1965, Liebert developed one of the first computer room air conditioning, or CRAC, units, enabling the precise control of temperature and humidity. The firm has slowly expanded its data center portfolio through internal product development and the acquisition of thermal and power management products like condensers, busways, and switches. Vertiv has global operations today; its products can be found in data centers in most regions throughout the world.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).